Table 2.
Primary efficacy endpoint | Mean: the difference in mean percentage loss of baseline body weight in the active-product versus placebo-treated group
Categorical: the proportion of subjects who lose at least 5% of baseline body weight in the active-product versus placebo-treated group |
Secondary efficacy endpoints | Should include, but are not limited to, changes in the following metabolic parameters:
|